AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer

Recruitingn/aAges 18 Years - anyAllQun Zhao
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study will evaluate whether an artificial intelligence (AI) system called DeepTRG can reliably assess cancer tissue removed during surgery after treatment given before surgery. It will include adults with stomach cancer or cancer at the junction between the stomach and the food pipe who have received treatment before surgery. Pathologists are doctors who examine tissue to diagnose disease. After cancer surgery, they assess how much living cancer remains and whether cancer is present in nearby lymph nodes. DeepTRG analyzes digital images of tissue slides to measure remaining cancer and describe tissue changes, such as scarring and inflammation. It combines information from the original tumor site and lymph nodes to produce a structured assessment. The main question is: \* How often can DeepTRG complete the required assessment and produce a clear result without a person correcting

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age 18 years or older. * Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II or III), diagnosed before neoadjuvant treatment. * Received neoadjuvant anticancer treatment before planned surgical resection. * Scheduled to undergo surgical resection with curative intent at the Fourth Hospital of Hebei Medical University, with routine pathological examination of the primary tumor site and regional lymph nodes. * Written informed consent obtained in accordance with the ethics-approved study protocol. Exclusion Criteria: * Non-adenocarcinoma malignancies, including squamous cell carcinoma, lymphoma, gastrointestinal stromal tumor, or neuroendocrine carcinoma. * Surgery for recurrent gastric or gastroesophageal junction cancer. * Previous inclusion of the patient's tissue or data in DeepTRG model training, grading-rule development, or parameter tuning. Patients will not be excluded because of a complete pathological response, positive surgical margins, poor-quality or unavailable slides, digitization failure, algorithm failure, or uncertain or unassessable DeepTRG results. Technical limitations identified after enrollment will be recorded and retained in the feasibility analysis. Patients who do not proceed to surgical resection will be documented in the study flow and will not contribute to the specimen-based primary outcome denominator.
๐Ÿ’Š

What it tests

  • AI-Based Digital Pathology Assessment of Treatment Response (DeepTRG)
๐Ÿ“

Where

1 site
the Fourth Hospital of Hebei Medical University
Shijiazhuang, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy